THE BASIC PRINCIPLES OF JOURNAL OF CLINICAL BREAST CANCER

Genomic sequencing Assessment of 733 HER2-amplified Major and metastatic breast tumours exposed considerable enrichment of mutations that activate RAS–MAPK signalling in Sophisticated tumours dealt with with prior anti-HER2 therapies121. These mutations, together with NF1 and HER2 activating mutations, add to resistance to tucatinib and neratinib